Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 153
- 试验地点
- 2
- 主要终点
- HF diagnosis
研究概览
简要总结
Objectives: The aim of this study is to determine whether growth differentiation factor-15 (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients on dialysis.
Background: Dialysis patients are at increased risk of HF. However, diagnostic utility of NT-proBNP as a biomarker is decreased in patients on dialysis. GDF15 and cNEP are biomarkers of distinct mechanisms that may contribute to HF pathophysiology in such cohorts.
Methods: We compare circulating concentrations of NT-proBNP, GDF15, and cNEP along with NEP activity in patients on chronic dialysis without and with HF, as diagnosed by clinical parameters and post-dialysis echocardiography. We use correlation, linear and logistic regression as well as receiver operating characteristic (ROC) analyses.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ESRD on either chronic hemodialysis (HD) or peritoneal dialysis (PD) for ≥3 months
排除标准
- •previous switch of the type of renal replacement therapy from HD to PD or vice versa
- •age <18 years
- •pregnancy
- •plasma exchange or apheresis in the past 6 months
- •unipolar pacemaker
- •history of whole extremity amputation
结局指标
主要结局
HF diagnosis
时间窗: Baseline (at study entry (diagnostic biomarker study))
Diagnosis of HF
次要结局
未报告次要终点
研究者
Michael Sören Balzer
Postdoctoral fellow
Hannover Medical School